Page results
-
Information about clinic-based after-care following treatment for childhood or teenage cancer at UCLH.
-
This information page aims to answer some of the questions you may have about receiving chimeric antigen receptor (CAR) T-cell therapy at University College London Hospitals NHS Foundation Trust (UCLH).
-
Events, classes and workshops at the Macmillan Support and Information Service (MSIS)
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
Latest news and developments in the Macmillan Support and Information Service
-
Information about staff who work in the Macmillan Support and Information Service.
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
This is information for women who have been given a diagnosis of adenomyosis.
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
Once again, UCLH has received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work
File results
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0235 - Hip and knee arthroplasty litigation
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0262 - Clinical trial participation